Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10 ILa | -0.99% | +11.11% | +185.71% |
Apr. 30 | XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 29 | Top Premarket Gainers | MT |
Sales 2022 | - | Sales 2023 | - | Capitalization | 5.28M 1.95B |
---|---|---|---|---|---|
Net income 2022 | -1M -369M | Net income 2023 | -1M -369M | EV / Sales 2022 | - |
Net cash position 2022 | 3.72M 1.37B | Net cash position 2023 | 2.01M 741M | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.72
x | P/E ratio 2023 |
-2.96
x | Employees | 5 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 93.3% |
1 day | -0.99% | ||
1 week | +11.11% | ||
Current month | +6.38% | ||
1 month | +6.38% | ||
3 months | +185.71% | ||
6 months | +194.12% | ||
Current year | +185.71% |
Managers | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 98-12-31 |
Doron Turgeman
CHM | Chairman | 56 | 14-12-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Director/Board Member | 57 | 20-01-28 | |
Director/Board Member | 53 | 17-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 10 | -0.99% | 2,311,161 |
24-05-15 | 10.1 | 0.00% | 3,705,881 |
24-05-12 | 10.1 | +12.22% | 17,421,300 |
24-05-09 | 9 | -2.17% | 862,354 |
24-05-08 | 9.2 | -2.13% | 1,021,025 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 16, 2024 at 10:24 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+185.71% | 14.99M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- XTLB Stock